These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 11259625)

  • 41. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.
    Muenster U; Grieshop B; Ickenroth K; Gnoth MJ
    Pharm Res; 2008 Oct; 25(10):2320-6. PubMed ID: 18523872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
    Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
    Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
    Koks CH; Crommentuyn KM; Hoetelmans RM; Burger DM; Koopmans PP; Mathôt RA; Mulder JW; Meenhorst PL; Beijnen JH
    Br J Clin Pharmacol; 2001 Jun; 51(6):631-5. PubMed ID: 11422025
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
    Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
    Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific increase in MDR1 mediated drug-efflux in human brain endothelial cells following co-exposure to HIV-1 and saquinavir.
    Roy U; Bulot C; Honer zu Bentrup K; Mondal D
    PLoS One; 2013; 8(10):e75374. PubMed ID: 24098380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coadministration of ABCB1/P-glycoprotein inhibitor elacridar improves tissue distribution of ritonavir-boosted oral cabazitaxel in mice.
    Loos NHC; Martins MLF; de Jong D; Lebre MC; Tibben M; Beijnen JH; Schinkel AH
    Int J Pharm; 2024 Jan; 650():123708. PubMed ID: 38135258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV protease inhibitors: garlic supplements and first-pass intestinal metabolism impact on the therapeutic efficacy.
    Berginc K; Trdan T; Trontelj J; Kristl A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):495-505. PubMed ID: 21104925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices.
    Berginc K; Trontelj J; Kristl A
    Drug Metab Pharmacokinet; 2010; 25(3):307-13. PubMed ID: 20610890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nicotine and cotinine increases the brain penetration of saquinavir in rat.
    Manda VK; Mittapalli RK; Bohn KA; Adkins CE; Lockman PR
    J Neurochem; 2010 Dec; 115(6):1495-507. PubMed ID: 20950334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
    Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
    Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.
    Lin F; Buil L; Sherris D; Beijnen JH; van Tellingen O
    Int J Cancer; 2013 Sep; 133(5):1222-33. PubMed ID: 23436212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice.
    Coles LD; Lee IJ; Hassan HE; Eddington ND
    J Pharm Sci; 2009 Aug; 98(8):2832-46. PubMed ID: 19116954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
    Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
    Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy.
    von Hentig N; Nisius G; Lennemann T; Khaykin P; Stephan C; Babacan E; Staszewski S; Kurowski M; Harder S; Haberl A
    Antivir Ther; 2008; 13(8):1039-46. PubMed ID: 19195329
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir.
    la Porte CJ; Li Y; Béïque L; Foster BC; Chauhan B; Garber GE; Cameron DW; van Heeswijk RP
    Clin Pharmacol Ther; 2007 Oct; 82(4):389-95. PubMed ID: 17361121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.